NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Proposed Single Technology Appraisal (STA)

Botulinum toxin type A for the prophylaxis of headaches in adults with chronic migraine

Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or
	appeal)
Manufacturers/sponsors	General
Allergan (botulinum toxin type A)	Board of Community Health Councils
	in Wales
Patient/carer groups	British National Formulary
Action on Pain Africa Transfer	Care Quality Commission
Afiya TrustBlack Health Agency	 Commissioning Support Appraisals Service
Brain and Spine Foundation	 Department of Health, Social Services
Chinese National Healthy Living	and Public Safety for Northern Ireland
Centre	Medicines and Healthcare products
Counsel and Care	Regulatory Agency
Equalities National Council	 National Association of Primary Care
Migraine Action	 Neurological Alliance of Scotland
Migraine Trust	NHS Alliance
Muslim Council of Britain	 NHS Commercial Medicines Unit
Muslim Health Network	 NHS Confederation
Neurological Alliance	 NHS Quality Improvement Scotland
 Neurosupport 	 Public Health Wales NHS Trust
Pain Concern	 Scottish Medicines Consortium
Pain Relief Foundation	 Wales Neurological Alliance
OUCH UK (Organisation for the	Descible comperator manufacturers
Understanding of Cluster Headache)	Possible comparator manufacturers
South Asian Health Foundation	• None
Specialised Healthcare Alliance	Relevant research groups
Professional groups	British Neurological Research Trust
Association of British Neurologists	 Cochrane Pain, Palliative Care and
British Association for Services to	Supportive Care Group
the Elderly	MRC Clinical Trials Unit
British Association for the Study of	National Institute for Health Research
Headache (BASH)	Policy Research Institute on Ageing
British Geriatrics Society	and Éthnicity
British Neuropathological Society	 Research Institute for the Care of
British Pain Society	Older People
Institute of Neurology	

National Institute for Health and Clinical Excellence

Provisional matrix for the proposed technology appraisal of botulinum toxin type A for the prophylaxis of headaches in adults with chronic migraine

Issue date: March 2011

Consultees	Commentators (no right to submit or appeal)
 National Pharmacy Association Primary Care Neurology Society Royal College of Anaesthetists (Faculty of Pain) Royal College of General Practitioners Royal College of Nursing Royal College of Pathologists Royal College of Physicians Royal Pharmaceutical Society Royal Society of Medicine United Kingdom Clinical Pharmacy Association 	 Evidence Review Group Evidence Review Group tbc National Institute for Health Research Health Technology Assessment Programme Associated Guideline Groups National Clinical Guidelines Centre
 Others Department of Health NHS Heywood, Middleton and Rochdale NHS South East Essex Welsh Assembly Government 	

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, Care Quality Commission and NHS Commercial Medicines Unit, and the *British National Formulary*.

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

Evidence Review Group (ERG)

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.

National Institute for Health and Clinical Excellence

Provisional matrix for the proposed technology appraisal of botulinum toxin type A for the prophylaxis of headaches in adults with chronic migraine

Issue date: March 2011

¹ Non manufacturer consultees are invited to submit statements relevant to the group they are representing.